12:00 AM
 | 
Feb 10, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

EB-1020 SR: Interim Phase IIa data

Interim data from the single-blind, U.S. Phase IIa EB-1020-ADHD-201 trial in 40 adult male ADHD patients showed that 150-250 mg doses of twice-daily EB-1020 SR significantly improved ADHD-RS-IV score by 22.4 points at week 4...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >